Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome

References

• Ganie MA, Vasudevan V, Wani IA, et al. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333–344. doi:10.4103/ijmr.IJMR_1937_17
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284. doi:10.1038/nrendo.2018.24
   PubMed Web of Science ®Google Scholar
• Zawadzki JK. Dunaif A.Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic Ovary Syndrome. Boston: Blackwell Scientific; 1992:377–384.
   Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi:10.1016/j.fertnstert.2003.10.004
   Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al.; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–4245. doi:10.1210/jc.2006-0178.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. doi:10.1016/j.fertnstert.2016.05.003
   PubMed Web of Science ®Google Scholar
• Lentscher JA, Decherney AH. Clinical Presentation and Diagnosis of Polycystic Ovarian Syndrome. Clin Obstet Gynecol. 2021;64(1):3–11. doi:10.1097/GRF.0000000000000563
   Web of Science ®Google Scholar
• Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–221. doi:10.1016/j.cca.2019.11.003
   PubMed Web of Science ®Google Scholar
• Berni TR, Morgan CL, Rees DA. Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab. 2021;106(9):e3369–e3380. doi:10.1210/clinem/dgab392
   PubMed Web of Science ®Google Scholar
• Wang Y, Ni Z, Li K. The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2021;37(12):1072–1078. doi:10.1080/09513590.2021.1942452
   PubMed Web of Science ®Google Scholar
• Enechukwu CI, Onuegbu AJ, Olisekodiaka MJ, et al. Oxidative stress markers and lipid profiles of patients with polycystic ovary syndrome in a Nigerian tertiary hospital. Obstet Gynecol Sci. 2019;62(5):335–343. doi:10.5468/ogs.2019.62.5.335
   Google Scholar
• Meczekalski B, Pérez-Roncero GR, López-Baena MT, et al. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36(4):289–293. doi:10.1080/09513590.2020.1730794
   PubMed Web of Science ®Google Scholar
• Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276. doi:10.3748/wjg.v23.i47.8263
   PubMed Web of Science ®Google Scholar
• Cardoso AC, de Figueiredo-Mendes C. Current management of NAFLD/NASH. Liver Int. 2021;41 Suppl 1:89–94. doi:10.1111/liv.14869
   Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract. 2005;11(5):319–324. doi:10.4158/EP.11.5.319
   Google Scholar
• Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(5):1741–1747. doi:10.1210/jc.2005-2774
   PubMed Web of Science ®Google Scholar
• Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496–501. doi:10.1016/j.cgh.2006.10.010
   PubMed Web of Science ®Google Scholar
• Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412–417. doi:10.1016/j.jhep.2007.04.012
   PubMed Web of Science ®Google Scholar
• Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25(1):212–220. doi:10.1093/humrep/dep380
   PubMed Web of Science ®Google Scholar
• Tan S, Bechmann LP, Benson S, et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab. 2010;95(1):343–348. doi:10.1210/jc.2009-1834
   Web of Science ®Google Scholar
• Hossain N, Stepanova M, Afendy A, et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol. 2011;46(4):479–484. doi:10.3109/00365521.2010.539251
   PubMed Web of Science ®Google Scholar
• Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341–347. doi:10.1002/uog.10084
   Web of Science ®Google Scholar
• Karoli R, Fatima J, Chandra A, et al. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci. 2013;6(1):9–14. doi:10.4103/0974-1208.112370
   PubMedGoogle Scholar
• Qu Z, Zhu Y, Jiang J, Shi Y, Chen Z. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med. 2013;11(9):725–732.
   PubMedGoogle Scholar
• Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynol Pol. 2014;65(6):416–421. doi:10.5603/EP.2014.0058
   PubMed Web of Science ®Google Scholar
• Romanowski MD, Parolin MB, Freitas AC, et al. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015;52(2):117–123. doi:10.1590/S0004-28032015000200008
   Google Scholar
• Macut D, Tziomalos K, Božić-Antić I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016;31(6):1347–1353. doi:10.1093/humrep/dew076
   PubMed Web of Science ®Google Scholar
• Cai J, Wu CH, Zhang Y, et al. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance. Int J Obes. 2017;41(9):1341–1347. doi:10.1038/ijo.2017.116
   Web of Science ®Google Scholar
• Mehrabian F, Jahanmardi R. Nonalcoholic Fatty Liver Disease in a Sample of Iranian Women with Polycystic Ovary Syndrome. Int J Prev Med. 2017;8:79. doi:10.4103/ijpvm.IJPVM_305_16
   Web of Science ®Google Scholar
• Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One. 2017;12(11):e0186136. doi:10.1371/journal.pone.0186136
   PubMed Web of Science ®Google Scholar
• Zhang J, Hu J, Zhang C, et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease. Exp Ther Med. 2018;15(5):4259–4264. doi:10.3892/etm.2018.5932
   Web of Science ®Google Scholar
• Harsha Varma S, Tirupati S, Pradeep TVS, et al. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Diabetes Metab Syndr. 2019;13(2):1065–1069. doi:10.1016/j.dsx.2018.12.020
   Web of Science ®Google Scholar
• Salva-Pastor N, López-Sánchez GN, Chávez-Tapia NC, et al. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. Ann Hepatol. 2020;19(3):251–257. doi:10.1016/j.aohep.2020.01.004
   Web of Science ®Google Scholar
• Chakraborty S, Ganie MA, Masoodi I, et al. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome. Indian J Med Res. 2020;151(4):333–341. doi:10.4103/ijmr.IJMR_610_18
   Web of Science ®Google Scholar
• Taranto DOL, Guimarães TCM, Couto CA, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center. Arch Endocrinol Metab. 2020;64(3):235–242. doi:10.20945/2359-3997000000242
   Web of Science ®Google Scholar
• Shengir M, Krishnamurthy S, Ghali P, et al. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol. 2020;26(44):7046–7060. doi:10.3748/wjg.v26.i44.7046
   Web of Science ®Google Scholar
• Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 2020;40(2):355–359. doi:10.1111/liv.14279
   PubMed Web of Science ®Google Scholar
• McCartney CR, Campbell RE. Abnormal GnRH Pulsatility in Polycystic Ovary Syndrome: recent Insights. Curr Opin Endocr Metab Res. 2020;12:78–84. doi:10.1016/j.coemr.2020.04.005
   PubMedGoogle Scholar
• Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. doi:10.1210/jc.2012-1382
   PubMed Web of Science ®Google Scholar
• Seidu T, McWhorter P, Myer J, et al. DHT causes liver steatosis via transcriptional regulation of SCAP in normal weight female mice. J Endocrinol. 2021;250(2):49–65. doi:10.1530/JOE-21-0040
   Web of Science ®Google Scholar
• Cui P, Hu W, Ma T, et al. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. J Steroid Biochem Mol Biol. 2021;208:105829. doi:10.1016/j.jsbmb.2021.105829
   Web of Science ®Google Scholar
• Li T, Zhang T, Cui T, et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. J Steroid Biochem Mol Biol. 2020;204:105752. doi:10.1016/j.jsbmb.2020.105752
   Web of Science ®Google Scholar
• Anzai Á, Marcondes RR, Gonçalves TH, et al. Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats. Sci Rep. 2017;7(1):13167. doi:10.1038/s41598-017-13451-8
   Web of Science ®Google Scholar
• Zhang Y, Meng F, Sun X, et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget. 2018;9(26):18180–18197. doi:10.18632/oncotarget.2447
   PubMedGoogle Scholar
• Jahromi BN, Borzou N, Parsanezhad ME, et al. Associations of insulin resistance, sex hormone-binding globulin, triglyceride, and hormonal profiles in polycystic ovary syndrome: a cross-sectional study. Int J Reprod Biomed. 2021;19(7):653–662. doi:10.18502/ijrm.v19i7.9476
   Web of Science ®Google Scholar
• Welt CK, Duran JM. Genetics of polycystic ovary syndrome. Semin Reprod Med. 2014;32(3):177–182. doi:10.1055/s-0034-1371089
   PubMed Web of Science ®Google Scholar
• Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med. 2011;28(12):1445–1454. doi:10.1111/j.1464-5491.2011.03460.x
   Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–441. doi:10.1007/s00535-013-0758-5
   PubMed Web of Science ®Google Scholar
• Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591–8638. doi:10.3390/ijms15058591
   PubMed Web of Science ®Google Scholar
• Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020;21(11):3863. doi:10.3390/ijms21113863
   PubMed Web of Science ®Google Scholar
• O’Reilly MW, House PJ, Tomlinson JW. Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol. 2014;143:277–284. doi:10.1016/j.jsbmb.2014.04.008
   PubMed Web of Science ®Google Scholar
• Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. doi:10.1177/1179558119874042
   Web of Science ®Google Scholar
• Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open. 2021;5(4):434–445. doi:10.1002/jgh3.12512
   PubMed Web of Science ®Google Scholar
• Hu W, Li L, Yang M, et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2013;98(1):290–298. doi:10.1210/jc.2012-2466
   PubMed Web of Science ®Google Scholar
• Wang GX, Zhao XY, Meng ZX, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. 2014;20(12):1436–1443. doi:10.1038/nm.3713
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97. doi:10.1016/j.metabol.2018.11.014
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42(2):92–108. doi:10.23736/S0391-1977.16.02563-3
   PubMed Web of Science ®Google Scholar
• Rudnicka E, Kunicki M, Suchta K, et al. Inflammatory Markers in Women with Polycystic Ovary Syndrome. Biomed Res Int. 2020;2020:4092470. doi:10.1155/2020/4092470
   PubMed Web of Science ®Google Scholar
• Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149(5):R219–R227. doi:10.1530/REP-14-0435
   PubMed Web of Science ®Google Scholar
• Appari M, Channon KM, McNeill E. Metabolic Regulation of Adipose Tissue Macrophage Function in Obesity and Diabetes. Antioxid Redox Signal. 2018;29(3):297–312. doi:10.1089/ars.2017.7060
   PubMed Web of Science ®Google Scholar
• Vonghia L, Magrone T, Verrijken A, et al. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS One. 2015;10(11):e0143380. doi:10.1371/journal.pone.0143380
   Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062–1079. doi:10.1016/j.metabol.2015.11.006
   PubMed Web of Science ®Google Scholar
• Krishnan A, Muthusami S, Periyasamy L, et al. Effect of DHT-Induced Hyperandrogenism on the Pro-Inflammatory Cytokines in a Rat Model of Polycystic Ovary Morphology. Medicina (Kaunas). 2020;56(3):100. doi:10.3390/medicina56030100
   Web of Science ®Google Scholar
• Kuliczkowska Plaksej J, Laczmanski L, Milewicz A, et al. Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls. Int J Endocrinol. 2014;2014:232975. doi:10.1155/2014/232975
   Web of Science ®Google Scholar
• Baranova A, Tran TP, Afendy A, et al. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med. 2013;11:133. doi:10.1186/1479-5876-11-133
   Web of Science ®Google Scholar
• Bohdanowicz-Pawlak A, Lenarcik-Kabza A, Brona A, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism. Endokrynol Pol. 2014;65(6):416. doi:10.5603/EP.2014.0058
   PubMed Web of Science ®Google Scholar
• Song X, Shen Q, Fan L, et al. Dehydroepiandrosterone-induced activation of mTORC1 and inhibition of autophagy contribute to skeletal muscle insulin resistance in a mouse model of polycystic ovary syndrome. Oncotarget. 2018;9(15):11905–11921. doi:10.18632/oncotarget.24190
   PubMedGoogle Scholar
• Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab. 2005;288(5):E1047–E1054. doi:10.1152/ajpendo.00361.2004
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96(2):801–810. doi:10.1172/JCI118126
   PubMed Web of Science ®Google Scholar
• Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 1981;108(4):1441–1449. doi:10.1210/endo-108-4-1441
   Web of Science ®Google Scholar
• Pani A, Gironi I, Di Vieste G, et al. From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: lifestyle and Pharmacological Management. Int J Endocrinol. 2020;2020:6276187. doi:10.1155/2020/6276187
   Web of Science ®Google Scholar
• Biernacka-Bartnik A, Kocełak P, Owczarek AJ, et al. Prediction of Insulin Resistance and Impaired Fasting Glucose Based on Sex Hormone-Binding Globulin (SHBG) Levels in Polycystic Ovary Syndrome. Int J Endocrinol. 2022;2022:6498768. doi:10.1155/2022/6498768
   Web of Science ®Google Scholar
• Laurent MR, Hammond GL, Blokland M, et al. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci Rep. 2016;6:35539. doi:10.1038/srep35539
   PubMed Web of Science ®Google Scholar
• Karabulut A, Yaylali GF, Demirlenk S, et al. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecol Endocrinol. 2012;28(2):111–114. doi:10.3109/09513590.2011.589929
   PubMed Web of Science ®Google Scholar
• Torres Fernandez ED, Adams KV, Syed M, et al. Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome. J Endocr Soc. 2018;2(8):949–964. doi:10.1210/js.2018-00131
   Web of Science ®Google Scholar
• Barber TM, Kyrou I, Randeva HS, Weickert MO. Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int J Mol Sci. 2021;22(2):546. doi:10.3390/ijms22020546
   PubMed Web of Science ®Google Scholar
• Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012;30(6):496–506. doi:10.1055/s-0032-1328878
   PubMed Web of Science ®Google Scholar
• Rostamtabar M, Esmaeilzadeh S, Tourani M, et al. Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome. J Cell Physiol. 2021;236(2):824–838. doi:10.1002/jcp.29912
   Web of Science ®Google Scholar
• Shorakae S, Ranasinha S, Abell S, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol. 2018;89(5):628–633. doi:10.1111/cen.13808
   PubMed Web of Science ®Google Scholar
• Rocha AL, Oliveira FR, Azevedo RC, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8:565. doi:10.12688/f1000research.15318.1
   Google Scholar
• Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and Its Management. Nutr Clin Pract. 2020;35(1):72–84. doi:10.1002/ncp.10449
   PubMed Web of Science ®Google Scholar
• Shele G, Genkil J, Speelman D, Systematic A. Review of the Effects of Exercise on Hormones in Women with Polycystic Ovary Syndrome. J Funct Morphol Kinesiol. 2020;5(2):35. doi:10.3390/jfmk5020035
   Google Scholar
• Lim SS, Hutchison SK, Van Ryswyk E, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):CD007506. doi:10.1002/14651858.CD007506.pub4
   PubMed Web of Science ®Google Scholar
• Abdolahian S, Tehrani FR, Amiri M, et al. Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):71. doi:10.1186/s12902-020-00552-1
   Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5. doi:10.1053/j.gastro.2015.04.005
   PubMed Web of Science ®Google Scholar
• Li C, Xing C, Zhang J, et al. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Transl Med. 2021;19(1):148. doi:10.1186/s12967-021-02817-2
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174. doi:10.1172/JCI13505
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253–270. doi:10.1042/CS20110386
   PubMed Web of Science ®Google Scholar
• Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev. 2009;89(3):1025–1078. doi:10.1152/physrev.00011.2008
   PubMed Web of Science ®Google Scholar
• Smith BK, Marcinko K, Desjardins EM, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311(4):E730–E740. doi:10.1152/ajpendo.00225.2016
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang D, Bu H, et al. The Effect of Metformin on Polycystic Ovary Syndrome in Overweight Women: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol. 2020;2020:5150684. doi:10.1155/2020/5150684
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N, Harborne L, et al. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract. 2008;62(9):1337–1343. doi:10.1111/j.1742-1241.2008.01825.x
   Web of Science ®Google Scholar
• Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol. 2011;75(4):520–527. doi:10.1111/j.1365-2265.2011.04093.x
   Web of Science ®Google Scholar
• Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518–533. doi:10.1161/CIRCULATIONAHA.104.475673
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: a Randomized Trial. Ann Intern Med. 2016;165(5):305–315. doi:10.7326/M15-1774
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184. doi:10.1053/j.gastro.2008.06.047
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661–677. doi:10.1007/s00404-017-4480-z
   PubMed Web of Science ®Google Scholar
• Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol. 2011;55(6):1383–1390. doi:10.1016/j.jhep.2011.03.016
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188. doi:10.1001/jama.298.10.1180
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. doi:10.1016/j.cmet.2013.04.008
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol. 2008;159(2):121–127. doi:10.1530/EJE-08-0097
   Web of Science ®Google Scholar
• Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne). 2014;5:140. doi:10.3389/fendo.2014.00140
   PubMed Web of Science ®Google Scholar
• Tian D, Chen W, Xu Q, et al. Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis. Minerva Med. 2021. doi:10.23736/S0026-4806.21.07085-3
   Web of Science ®Google Scholar
• Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017l;35(1):121–127. doi:10.1016/j.rbmo.2017.03.023
   PubMed Web of Science ®Google Scholar
• Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215–218. doi:10.1111/dom.13053
   PubMed Web of Science ®Google Scholar
• Kahal H, Abouda G, Rigby AS, et al. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol. 2014;81(4):523–528. doi:10.1111/cen.12369
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011;3:25–35. doi:10.2147/IJWH.S11304
   PubMedGoogle Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13. doi:10.2147/CLEP.S37559
   PubMed Web of Science ®Google Scholar
• Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis. 2014;24(2):132–139. doi:10.1016/j.numecd.2013.04.016
   PubMed Web of Science ®Google Scholar
• Diri H, Karaburgu S, Acmaz B, et al. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(1):42–45. doi:10.3109/09513590.2015.1080679
   PubMed Web of Science ®Google Scholar
• Muneyyirci-Delale O, Kaplan J, Joulak I, et al. Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. Gynecol Endocrinol. 2013;29(5):474–477. doi:10.3109/09513590.2013.769515
   PubMed Web of Science ®Google Scholar
• Adeyanju OA, Falodun TO, Michael OS, et al. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(6):1055–1066. doi:10.1007/s00210-020-01809-1
   PubMed Web of Science ®Google Scholar
• Ebrahimi FA, Samimi M, Foroozanfard F, et al. The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Exp Clin Endocrinol Diabetes. 2017;125(6):353–359. doi:10.1055/s-0042-117773
   PubMed Web of Science ®Google Scholar
• Rahmani E, Samimi M, Ebrahimi FA, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. Mol Cell Endocrinol. 2017;439:247–255. doi:10.1016/j.mce.2016.09.008
   PubMed Web of Science ®Google Scholar
• Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009;94(10):3842–3848. doi:10.1210/jc.2009-0870
   PubMed Web of Science ®Google Scholar
• Nagashimada M, Ota T. Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life. 2019;71(4):516–522. doi:10.1002/iub.1991
   PubMed Web of Science ®Google Scholar
• Javed Z, Papageorgiou M, Deshmukh H, et al. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients. 2019;11(1):188. doi:10.3390/nu11010188
   PubMed Web of Science ®Google Scholar
• Ezzat RS, Abdallah W, Elsayed M, et al. Impact of bariatric surgery on androgen profile and ovarian volume in obese polycystic ovary syndrome patients with infertility. Saudi J Biol Sci. 2021;28(9):5048–5052. doi:10.1016/j.sjbs.2021.05.022
   Web of Science ®Google Scholar
• Christ JP, Falcone T. Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). Obes Surg. 2018;28(8):2171–2177. doi:10.1007/s11695-018-3155-6
   PubMed Web of Science ®Google Scholar
• Li YJ, Han Y, He B. Effects of bariatric surgery on obese polycystic ovary syndrome: a systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(6):942–950. doi:10.1016/j.soard.2019.03.032
   PubMed Web of Science ®Google Scholar
• Gomez-Meade CA, Lopez-Mitnik G, Messiah SE, et al. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes. 2013;4(3):64–69. doi:10.4239/wjd.v4.i3.64
   Google Scholar